|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 19/073 | |
| C07H 19/10 | |||
| C07H 21/04 | |||
| C12N 15/115 |
| (11) | Number of the document | 2558586 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11769393.7 |
| Date of filing the European patent application | 2011-04-12 | |
| (97) | Date of publication of the European application | 2013-02-20 |
| (45) | Date of publication and mention of the grant of the patent | 2016-10-12 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/032017 |
| Date | 2011-04-12 |
| (87) | Number | WO 2011/130195 |
| Date | 2011-10-20 |
| (30) | Number | Date | Country code |
| 323145 P | 2010-04-12 | US |
| (72) |
SCHNEIDER, Daniel, J., US
HISAMINATO, Akihiko, JP
WAUGH, Sheela, US
RESNICOW, Daniel, US
NAGABUKURO, Akira, JP
ONO, Toshihide, JP
|
| (73) |
Otsuka Pharmaceutical Co., Limited,
2-9, Kanda-Tsukasamachi, Chiyoda-ku Tokyo 101-8535,
JP
Somalogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, US |
| (54) | APTAMERS TO -NGF AND THEIR USE IN TREATING -NGF MEDIATED DISEASES AND DISORDERS |
| APTAMERS TO -NGF AND THEIR USE IN TREATING -NGF MEDIATED DISEASES AND DISORDERS |